Summary
While former President Trump claims credit for recent drops in U.S. prescription drug prices, experts suggest that the Biden administration's Inflation Reduction Act, allowing Medicare to negotiate drug costs, and increased competition from generic drugs are more significant factors. The actual impact of Trump's "most favored nation" deals remains unclear.